BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

...virus vaccine in April. The CpG 1018 adjuvant is used in Dynavax’s marketed HBV vaccine, Heplisav-B...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

...benefit from use of the adjuvant, which is used in the company’s marketed HBV vaccine, Heplisav-B...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

...had been interim co-presidents since May, when the company restructured to focus on HBV vaccine Heplisav-B...
BioCentury | Oct 4, 2019
Company News

Management tracks: J&J hires Bayer’s Swanson; plus Torque, Dynavax, Pact, Deciphera, NextCure, Retrophin, Verve, Jnana and more 2017 (see "Backpacks for CARs" ). Dynavax Technologies Corp. (NASDAQ:DVAX), which markets HBV vaccine Heplisav-B...
BioCentury | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

...raise up to $60 million, and priced the offering early Thursday. Dynavax markets HBV vaccine Heplisav-B...
BioCentury | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

...and explore strategic alternatives for its cancer immunotherapy programs to focus on its HBV vaccine, Heplisav-B...
BioCentury | Mar 22, 2019
Financial News

Dynavax commercializing Heplisav-B with $75M debt financing

...To fund the commercialization of its Heplisav-B HBV vaccine, Dynavax announced March 18 it was drawing...
...Staff Writer Heplisav-B (Brand), HBsAg-1018 (Compound #), V270 (Former compound #), Heplisav (Informal), HBV vaccine (Informal), Heplisav-B...
...Brand), HBsAg-1018 (Compound #), V270 (Former compound #), Heplisav (Informal), HBV vaccine (Informal), Heplisav-B (Other), HBV-ISS vaccine...
BioCentury | Jan 5, 2019

Ready to launch

...Inc. / Roche (SIX:ROG; OTCQX:RHHBY) Hemlibra emicizumab-kxwh Hemophilia A U.S. $115.1 Dynavax Technologies Corp. (NASDAQ:DVAX) Heplisav-B...
BioCentury | Jan 10, 2018
Company News

Dynavax launches Heplisav-B in the U.S.

...Dynavax Technologies Corp. (NASDAQ:DVAX) launched Heplisav-B in the U.S. to prevent infection caused by all known... the U.S. to prevent infection caused by all known subtypes of HBV in adults. Heplisav-B...
...The drug has a wholesale acquisition cost (WAC) of $230 per regimen. The FDA approved Heplisav-B...
BioCentury | Jan 9, 2018

Stars in China

...HER2-positive early breast cancer and HER2-positive metastatic gastric cancer Dynavax Technologies Corp. (NASDAQ:DVAX) FDA approves Heplisav-B...
Items per page:
1 - 10 of 211